Tallon et al. explored a novel therapeutic approach for Alzheimer’s disease by investigating the dendrimer-based delivery of 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP), a potent inhibitor of neutral sphingomyelinase 2 (nSMase2). Here, SMPD3 is linked to early-onset autosomal dominant Alzheimer disease.